Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection

ConditionPre-Eclampsia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCentre Hospitalier Intercommunal Creteil

About this trial

Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and / or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

pregnant women

With or without vascular pathology

Disqualifiers

refusal to participate

multiple pregnancy

major fetal malformation diagnosed during pregnancy follow-up

Trial population

pregnant women with or without vascular pathology

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • collect of placenta, blood and urinary samples at delivery

    Other intervention

    collect of placenta, blood and urinary samples at delivery

Treatment groups

500 Participants
are divided into 2 treatment groups
Group A: Vascular group1 intervention
Group B: Control group1 intervention

Trial outcomes

Primary outcomes

1

genomic analysis on placenta

by chromatin immunoprecipitation-sequencing (ChIP-seq)

Time frame
day of delivery

Secondary outcomes

1

genomic analysis on blood

by ChIP-seq

Time frame
day of delivery
2

genomic analysis on placenta

by immunohistochemistry an polymerase chain-reaction

Time frame
day of delivery
3

VEGF blood level

Time frame
day of delivery
4

PLGF blood level

Time frame
day of delivery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.